Researchers created hybrid nanoparticles by chemically linking nicotinic acid (vitamin B3's active form) to chitosan, producing 100-140 nanometer carriers that delivered resveratrol more effectively against HeLa cervical and HT-29 colon cancer cells than either free resveratrol or standard chitosan formulations. The nicotinic acid modification improved the carrier's solubility at physiological pH and buffering capacity while contributing its own anticancer effects in an additive manner. Crucially, healthy fibroblast cells showed minimal toxicity, suggesting selective cancer cell targeting. This represents an intriguing convergence of nutraceutical research with nanotechnology, potentially addressing resveratrol's notorious bioavailability limitations that have long hampered its clinical translation. The dual bioactive approach—combining a polyphenol with a B vitamin in a single delivery system—offers a novel strategy for cancer therapeutics. However, the in vitro findings require validation in animal models and human studies. The enhanced selectivity for cancer cells over healthy tissue, if confirmed in vivo, could represent a meaningful advance in targeted cancer therapy using naturally-derived compounds rather than synthetic drugs.